Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
Clinical trial NCT06602193 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06602193
- Sponsor
- Denali Therapeutics Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-24
- Primary completion
- 2027-03-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.